Skip to content Menu
Science Chronicle

Science Chronicle

A Science and Technology Blog

Sidebar
  • Home
  • PODCASTS
  • About
  • ARCHIVES
  • Award for R. Prasad

Category: Gilead Sciences

Posted on October 17, 2020October 17, 2020

WHO supported Solidarity trial finds remdesivir ineffective but WHO prequalifies it anyway

Even as WHO supported Solidarity Therapeutics Trial found remdesivir to be ineffective in reducing mortality and duration of hospital stay, the global body prequalified the drug the same day the…

Continue Reading
Posted on October 16, 2020October 16, 2020

Remdesivir, other repurposed drugs ineffective, says WHO’s Solidarity trial

WHO’s Solidarity Therapeutics Trial, the largest randomised control trial carried out in the world during the pandemic, has found that four repurposed drugs — remdesivir, interferon, hydroxychloroquine and lopinavir/ritonavir regimes…

Continue Reading
Posted on June 23, 2020

Gilead to begin testing inhaled remdesivir for early-stage treatment

Gilead plans to begin a Phase-1 clinical trial in August of an inhaled version of remdesivir for early-stage COVID-19 treatment outside of hospital settings. The drug is currently approved for…

Continue Reading
Posted on May 24, 2020

Remdesivir trial results: NEJM, NIAID and Gilead provide conflicting information

Information shared by the three stakeholders — NEJM, NIAID and Gilead — on critical issues about whether the drug’s ability to reduce mortality is statistically significant and which category of…

Continue Reading
Posted on January 6, 2016December 13, 2017

India rejects patent claims on two HIV/AIDS drugs

The Indian Patent Office (IPO) has rejected applications from two U.S. pharmaceutical companies on grounds of “evergreening”, raising hopes of a further lowering of prices of two life-saving drugs used…

Continue Reading
Follow Science Chronicle on WordPress.com

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 10,781 other followers

Archives

Social

  • View Prasad.Ravindranath’s profile on Facebook
  • View @RPrasad12’s profile on Twitter
  • View Prasad.Ravindranath@gmail.com’s profile on Google+

Recent Posts

  • India will add four million more cases by May 1, says Giridhara Babu April 10, 2021
  • 180 deaths following COVID-19 vaccination reported in India April 9, 2021
  • Health Ministry reveals the names of SEC members for vaccine approval April 5, 2021
  • What is driving the second wave in India? April 3, 2021
  • SEC allows Bharat Biotech to unblind all participants above 45 years April 1, 2021

Most Read Posts

  • 180 deaths following COVID-19 vaccination reported in India
  • IGIB: In vaccinated people, Covishield first dose is highly immunogenic if already infected
  • India will add four million more cases by May 1, says Giridhara Babu
  • No correlation between Ct values of PCR test and COVID-19 severity
  • 65 papers from India retracted for image falsification/fabrication, errors
  • Gilead to begin testing inhaled remdesivir for early-stage treatment
  • Sadhguru Jaggi Vasudev, stop spreading vaccine misinformation
  • Home
  • PODCASTS
  • About
  • ARCHIVES
  • Award for R. Prasad
  • Home
  • PODCASTS
  • About
  • ARCHIVES
  • Award for R. Prasad
Create a website or blog at WordPress.com
Top
Follow Science Chronicle on WordPress.com

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 10,781 other followers

Archives

Cancel

 
Loading Comments...
Comment
    ×